Collagenase in the Treatment of Dupuytrens Disease

Completed · Phase 3 · Has a placebo group

Conditions studied: Dupuytren's Disease

In brief

The purpose of the study is to determine if collagenase will reduce the degree of contracture in the primary joint in subjects with Dupuytren's disease. This study was designed to be part of the larger clinical program, for adult patients with Dupuytren's contracture with a palpable cord, where the data from 2 pivotal Placebo-Controlled studies (AUX-CC-857 and AUX-CC-859) and 7 non-pivotal studies were evaluated.

Key facts

Study ID

NCT00260429

Run by

Stony Brook University

People needed

38

Starts

2003-06-01

Expected to finish

2008-04-01

Last updated by the study team

2010-12-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects were at least 18 years of age, of either sex or any race.
• Subjects had residual Dupuytren's disease with a fixed-flexion deformity of the finger(s) of at least 20 degrees or greater, caused by a palpable cord.
• Subjects had a positive "table-top test" defined as the inability to simultaneously place their affected finger(s) and palm flat against a table top.
• Subjects must have been willing to participate in and complete the study, and comply with its procedures by signing an IRB approved written consent form.
• Subjects must have been able to understand and adhere to the visit schedule. They must have been able to follow study procedures and instructions, and have agreed to report concomitant medications and adverse events accurately and consistently.
• Women of childbearing potential must have agreed to use an acceptable method of birth control or must have been surgically sterilized (hysterectomy or tubal ligation). Women of childbearing age had a urine pregnancy test on Day 0 (day of injection) prior to the injection.

You may not qualify if…

• Women who were nursing or who were pregnant (as evidenced by a positive urine pregnancy test at the time of enrollment).
• Subjects who had participated in an investigational drug trial within 30 days of enrollment in this study.
• Subjects who had received surgery for Dupuytren's disease within 30 days of enrollment in this study.
• Subjects who had a known allergy to AA4500 or any of the inactive ingredients in the AA4500 injection.
• Subjects who had a known allergy to doxycycline.
• Subjects who had a medical condition that would have made them unsuitable for enrollment.

Where it is running

• Stony Brook University Hospital and Mediacl Center — Stony Brook, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.